Dunlop A. Sinclair (CIK 1721108) reported 13 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-05-14). Recent activity: Sell APLS (161,567 shares), Sell APLS (3,062 shares), Sell APLS (5,744 shares), Sell APLS (7,961 shares), Sell APLS (3,544 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 161,567 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 3,062 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 5,744 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 7,961 | $0 |
| 2026-05-14 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 3,544 | $0 |
| 2026-01-05 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Buy | 7,961 | $0 |
| 2025-10-15 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 4,787 | $0 |
| 2025-10-15 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 31,092 | $737,502 |
| 2025-10-15 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 3,837 | $0 |
| 2025-10-02 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 31,092 | $702,057 |
| 2025-10-02 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 3,837 | $0 |
| 2025-09-19 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 31,092 | $713,561 |
| 2025-09-19 | Apellis Pharmaceuticals, Inc. (APLS) | Director | Sell | 3,837 | $0 |
Source: SEC Form 4 filings · as of 2026-05-14